Library — CHDR

Search

Filter

Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation.

Alvarez-Jimenez R, Baakman AC, Stevens J, Goulooze SC, Hart EP, Rissmann R, van Gerven JM, Groeneveld GJ

Journal of psychopharmacology (Oxford, England), 2018 Feb; 31(2):192-203

View publication
An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine.

Baakman AC, Alvarez-Jimenez R, Rissmann R, Klaassen ES, Stevens J, Goulooze SC, den Burger JCG, Swart EL, van Gerven JMA, Groeneveld GJ

British journal of clinical pharmacology, 2018 Feb; 83(8):1676-1687

View publication
The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468.

Treiber A, de Kanter R, Roch C, Gatfield J, Boss C, von Raumer M, Schindelholz B, Muehlan C, van Gerven J, Jenck F

The Journal of pharmacology and experimental therapeutics, 2018 Feb; 362(3):489-503

View publication
Pharmacodynamic response profiles of anxiolytic and sedative drugs.

Chen X, Broeyer F, de Kam M, Baas J, Cohen A, van Gerven J

British journal of clinical pharmacology, 2017 Apr; 83(5):1028-1038

View publication
Effects of a single, oral 60 mg caffeine dose on attention in healthy adult subjects.

Wilhelmus MM, Hay JL, Zuiker RG, Okkerse P, Perdrieu C, Sauser J, Beaumont M, Schmitt J, van Gerven JM, Silber BY

Journal of psychopharmacology (Oxford, England), 2017 Jan; 31(2):222-232

View publication
Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation.

Schrier L, Zuiker R, Merkus FW, Klaassen ES, Guan Z, Tuk B, van Gerven JM, van der Geest R, Groeneveld GJ

British journal of clinical pharmacology, 2016 Oct; 83(4):721-731

View publication
Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.

Alvarez-Jimenez R, Groeneveld GJ, van Gerven JM, Goulooze SC, Baakman AC, Hay JL, Stevens J

British journal of clinical pharmacology, 2016 Sep; 82(4):1011-21

View publication
Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects.

Spiegelstein O, Stevens J, Van Gerven J, Nathan PJ, Maynard JP, Mayleben DW, Hellriegel E, Yang R

Journal of psychopharmacology (Oxford, England), 2016 Sep; 30(10):983-93

View publication
Measuring blood-brain barrier penetration using the NeuroCart, a CNS test battery.

Groeneveld GJ, Hay JL, Van Gerven JM

Drug discovery today. Technologies, 2016 Jun

View publication

«
1
2
3
4
5
6
7
8
9
»